Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > So,
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(281)
•••
Comment by IainCaimbeulon Apr 19, 2024 4:31pm
53 Views
Post# 35998853

RE:RE:RE:RE:RE:RE:So,

RE:RE:RE:RE:RE:RE:So,
Nailbiter2 wrote:
IainCaimbeul wrote:
Nailbiter2 wrote: I answered your question. The show goes on regardless of the timing of Q4 release.

IainCaimbeul wrote: You added NO info to my question.
Nailbiter2 wrote:
IainCaimbeul wrote: if we have to delay to the end of May 2024 to finally reveal 2023 ye/q4 does that mean stage gets an automatic delay on the mid-May q1 2024? 
Asking for a friend.


Tell your friend that YE filings are the only ones that are audited.
If we fail to pay the auditors before May 31st, Q1-24 is still a go for mid May.
Kinda makes Q4-23 redundant at that point... So I've been told.
You and your friend have a pleasant life.






Call it a draw, we have bigger fish to fry here.

There's a big one that just fried about an hour ago outside a courthouse.
He fried up real good.


You made a funny out of a man setting himself on fire?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities